Round-up April 4th – April 23rd

Veritas Genomics are offering a $999 genome, ordered through your genome, with results accessible via an App. You can see the list of conditions and traits that they will report on here.

Astra-Zeneca are partnering with Venter’s HLI (which recently raised $220M in venture funding) to analyze 2 million WGS, in a 10 year, $100ms deal.

Kaiser have announced a sequencing initiative for 500,000 of their members, with the aim of drawing actionable information into their members’ EHRs

AncestryDNA have received an undisclosed amount of funding, and are being quiet about what the money will be used for

Wellderly Case-Control analysis published: Wellderly are those with the healthy-aging phenotype, the “disease-free aging in humans without medical interventions.” The cohort of 511 “Wellderly” have a significantly lower genetic risk for Alzheimer disease and coronary artery disease, but no difference for diabetes or cancer risk. One of the first examples of WGS case-control looking at both rare and common variants.

Across nearly 600,000 individuals, 13 were found that should have died from disease — so called genetic superheros. Following up with these 13 is impossible because of how they were consented, and Daniel MacArthur uses this to make a call for “a willingness of participants to donate their genomic and clinical data, and a commitment by researchers and regulators to overcome the daunting obstacles to data sharing on a global scale.”

New development for gene-editing: “the new technique basically means that CRISPR just went from handling DNA like a meat cleaver — to handling it like a scalpel”

A second Chinese group have published the results of using CRISPR on (non-viable) human embryos, attempting to knock out the CCR5 gene, a mutation known to protect against HIV. 4 of the 26 embryos were successfully edited.

AMP has published cost analysis of WGS. Labs reported costs of

  • five to 50 genes for solid tumor samples: $578 to $908.
  • tumor panel with greater than 50 genes: $1,948.
  • hearing loss sequencing analysis: $1,048 and $1,949.
  • exome sequencing: $1,499 to $3,388.

The article also performs a cost-benefit analysis of WGS, with all scenarios they test coming out on the benefit side.

The Broad Institute, who maintains the most frequently used variant-calling pipeline, GATK, is launching GATK in the cloud, across all the main providers.

Envision, a spin-out company from Hudson-Alpha, are offering WGS in a clinical setting for $6500. They claim analysis times of 1-1.5 hours, based on their software, Codi. The group has been controversial in its advocacy of WGS rather than WES. They say the number of variants that end up being analyzed are almost identical for exomes versus genomes, but some diagnoses are possible with WGS and not in WES.

Pharmacogenomics Clinical Annotation Tool (PharmCAT), is being developed as part of a consortia. It will annotate a VCF with all CPIC level-A variants, to be published under Creative Commons

DNAFit, a company that will give you tailored training advice based on your genetics for $140, has published a study claiming that there test makes a difference to performance

A nice write up of the decisions couples face when considering pre-implantation genetic diagnosis, from Genome Magazine

GWAS hits for “subjective well-being”, and for cognitive function

Hypo-methylation at the MAOA locus has been linked to panic disorders. New research shows that those patients who undergo successful Cognitive Behavioral Therapy have their methylation patterns returned to more normal levels

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s